KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Asset Writedowns and Impairment (2020 - 2025)

Exact Sciences (EXAS) has disclosed Asset Writedowns and Impairment for 6 consecutive years, with $543000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Asset Writedowns and Impairment fell 97.1% to $543000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $845.0 million, a 2599.72% increase, with the full-year FY2024 number at $869.5 million, up 139909.66% from a year prior.
  • Asset Writedowns and Impairment was $543000.0 for Q3 2025 at Exact Sciences, down from $6.3 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $838.2 million in Q4 2024 to a low of $10000.0 in Q4 2021.
  • A 5-year average of $69.9 million and a median of $4.4 million in 2024 define the central range for Asset Writedowns and Impairment.
  • Peak YoY movement for Asset Writedowns and Impairment: plummeted 99.9% in 2021, then surged 34220.0% in 2022.
  • Exact Sciences' Asset Writedowns and Impairment stood at $10000.0 in 2021, then soared by 34220.0% to $3.4 million in 2022, then tumbled by 83.92% to $552000.0 in 2023, then skyrocketed by 151741.3% to $838.2 million in 2024, then plummeted by 99.94% to $543000.0 in 2025.
  • Per Business Quant, the three most recent readings for EXAS's Asset Writedowns and Impairment are $543000.0 (Q3 2025), $6.3 million (Q1 2025), and $838.2 million (Q4 2024).